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Abstract 
Objective: Antibiotics reserve (ARs) are given as a last line of treatment when other antibiotics are no longer effec-
tive. Rising threat of antimicrobial resistance makes growing use of ARs a real problem to patient safety. A single 
centre interventional cohort study was conducted in order to measure impact on clinical outcomes of A-team pro-
gramme with limited human resources in a short period. A-team programme started on 01. September 2017.
Results: In 3 months preintervention and 3 months intervention period, from 3038 and 3156 hospitalized 
adult patients, 249 (59% of them were male, median age = 69 years) and 96 (51% of them were male, median 
age = 70 years) received parenteral ARs. Total duration of hospitalization of patients on AR was reduced from 28 to 
17 days of hospitalization on 100 patient-days (OR = 1.92; 95% CI 1.83–2.01; p < 0.001) with no statistical significant 
difference in rehospitalisation due to infection of patients that were treated with ARs within 2 months after discharge. 
Despite short period of time and limited human resources, A-team restrictive interventions rationalised parenteral AR 
use and led to positive impact on clinical outcomes. These results could help our and other A-teams in similar situa-
tion in continuing with the programme to bring more evidence.
Keywords: Antibiotic reserve, Antimicrobial stewardship, Multidisciplinary approach, Limited human resources, 
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Introduction
With estimated 10 million deaths until 2050, antimicro-
bial resistance (AMR) will reach the first place of main 
cause of deaths, before deaths from carcinoma or dia-
betes [1]. In addition to slow development of new anti-
microbial drugs, these led to creation of list of priority 
pathogens by World Health Organization (WHO) to sup-
port research of new and effective drugs [2]. Moreover, 
to preserve existing antibiotics, WHO also updated their 
Essential Medicines List for antibiotics, and designated 
all drugs into access (first line choice), watch and reserve 
(last line antibiotics). Antibiotic reserves (ARs) should be 
given as the last line of treatment when other antibiot-
ics no longer work [2]. ARs are useful for a wide range 
of infections but, because of need to reduce the risk of 
development of resistance and its relatively high cost, it 
would be inappropriate to recommend their unrestricted 
use [3]. Despite this, their use and resistance are increas-
ing worldwide [4-7]. As a result, importance of antimi-
crobial stewardship teams (A-team) has never been more 
substantial [8-10].
A cost–benefit analysis showed that maintaining 
A-team leads to improvements in quality and cost of 
care with positive clinical outcomes (i.e. by assuring 
appropriate treatment), compared with standard of 
care [11]. Additionally, effect of AMR policies seems to 
be variable. Absence of progress is partly due to insuf-
ficient evidence base to inform policymakers about 
effectiveness, generalizability, and cost-effectiveness of 
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initiatives [12]. Despite evidence of benefits of A-team 
implementation, it has still not been recognized and 
applied in Croatia. Some reasons: not enough infec-
tious disease (ID) specialists or incorporated clinical 
microbiologists in majority of hospitals or no clinical 
pharmacists included in clinical medicine.
In this study, we aimed to determine whether imple-
mentation and multidisciplinary approach of A-team, 
in a short period of time, compared with period with-
out A-team, would rationalize number of patients on 
parenteral AR, without negatively affecting clinical 
outcomes in acute secondary care public hospital with 
before mentioned obstacles. Achieving the goal could 
make A-team to continue with the programme and 
serve as example for other hospitals and countries with 
limited human resources.
Main text
Methods
Study design and setting
This was a single-centred cohort before and after 
study. The study was performed in 325 adult-bed acute 
secondary care general hospital “Dr. Tomislav Bardek” 
Koprivnica, Croatia, across all adult wards which cov-
ers area with 115 584 inhabitants [13]. Included were 
all hospitalized patients receiving parenteral ARs 
which were actively used in hospital and were on basic 
medical reimbursement list of Croatian health insur-
ance fund (piperacillin/tazobactam, ceftazidime, cef-
triaxone, cefepime, meropenem, ertapenem, amikacin, 
vancomycin and colistin (polymyxin E) as well as cip-
rofloxacin due to evidence of growing resistance [14, 
15]. Chosen were two periods of 3  months (preinter-
vention period from 01. May 2017 to 31. July 2017 and 
intervention period from 01. September 2017 to 30. 
November 2017). The A-team intervention started on 
01. September 2017.
A-team consisted of multidisciplinary specialists 
such as 1 FTE ID specialist, 0.5 FTE clinical microbiol-
ogist and 0.5 FTE clinical pharmacist who cooperated 
on daily basis except after working hours, on weekends 
and holidays. One FTE is defined as full time equiv-
alent of eight working hours from Monday to Friday. 
Outside that time, an attending physician (a specialist) 
could prescribe AR, which was reviewed on the first 
working day by A-team. In that way, there was no delay 
in the start of antibiotic treatment.
Criteria proposed by Centre for Disease Control and 
Prevention for appropriate use of antibiotics in hospi-
tal settings were described in Standard operative pro-
cedure and followed [16, 17].
Type and target of the intervention
We chose restrictive intervention due to evidence of 
more significant immediate effect on prescribing than 
education and persuasion interventions [18]. It included: 
a review of medical record by A-team, an interpretation 
of laboratory susceptibilities from clinical microbiologist, 
prior audit of ID specialist (bedside consultation) with 
validation and authorization of prescriptions by clinical 
pharmacist. The criteria for prescribing AR were: patients 
with symptoms that were significant or severe (with 
median definition of fever ≥ 37.5  °C [19]), high risk of 
complications or the infection is not resolving. This rec-
ommendation was communicated to treating physicians, 
but final commitment of implementing clinical decisions 
was the responsibility of the treating team. A recommen-
dation was also documented in the medical record.
Inclusion and exclusion criteria
All adult inpatients who received parenteral AR were 
included in the study. Exclusion criteria were patients 
already under the care of ID physician, being treated in 
preintervention period or paediatric patients.
Assessment of the outcomes
Primary outcomes were number, proportion of patients 
with ARs prescribed and total duration of hospitalization 
of patients on ARs per 100 patient days. The number of 
rehospitalized patients due to infection which were pre-
viously treated with AR in 1st, 2nd and 3rd month after 
discharge was also investigated. Diagnoses for the infec-
tion were following according to WHO International 
Statistical Classification of Diseases and Related Health 
Problems ICD-10 descriptive codes (ICD) [20]: diseases 
of respiratory system (J00-J99) and certain infectious and 
parasitic diseases (A00-B99). Empirical usage and thera-
peutic medication were not distinguished in this study. 
Data were collected monthly from hospital computer 
system.
Secondary outcomes were the duration of treatment 
with AR prescribed per 100 patient days. Demographic 
information (age, gender, main ICD at hospital admis-
sion, presence of fever, comorbidities and admitted ward) 
was obtained to assess risk factors for starting AR.
Preintervention period
Preintervention period consisted of prescribing ARs 
on AR computer ordered form in all adult wards. Phy-
sician authorized for prescribing AR filled AR form 
with basic information on patient and drug (patient′s 
name and date of birth, working diagnosis, name of 
AR and daily dosage). This authorization was sent in 
printed form to the hospital pharmacy. The pharmacist 
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and an experienced pharmacy technician checked the 
validity and dispensed AR for 2 or 3  days of therapy. 
Every further prolongation of AR therapy required a 
new authorization by authorized physician and valida-
tion from a pharmacist. The pharmacist did not have 
access to medical record for further information (e.g., 
allergy).
Preintervention period targeted at the same ARs 
with the same criteria for prescribing and same pri-
mary and secondary outcomes but without A-team.
Statistical analysis
Patient characteristics in both periods were compared 
using Wilcoxon rank-sum test for continuous variables 
and Fisher exact test for binary categorical variables.
The number of rehospitalization due to infection 
after 1, 2 and 3  months of discharge were compared 
using Fisher exact test. Duration of hospitalization of 
patients on AR and average duration under AR treat-
ment were compared using a Chi-squared test.
All p values only less than 0.05 were considered sta-
tistically significant. Statistical analysis was performed 
in R, version 3.4.4. [21].
Results
Patient characteristics
Baseline characteristics are shown in Table 1. There was 
no statistically significant difference between baseline 
characteristics of proportion of patients on ARs in both 
periods. Median ages of patients on AR were 69 and 
70  years in preintervention and intervention period. 
Most patients on AR had fever and were admitted to 
Intensive care unit (ICU) with no statistical difference in 
comorbidities and main ICD diagnosis on admission in 
both periods.
Preintervention and intervention period
In preintervention period, printed forms for all 249 
patients were validated and approved. During interven-
tion, A-team evaluated 354 patients of which 96 (27%) 
consulted on ARs, while in majority (73%) of patients 
recommended other antibiotic (which was not AR). The 
acceptance rate was 100% for all evaluated patients.
Results on primary outcomes
Results are shown in Table 2. Duration of hospitalization 
of patients on AR in preintervention and intervention 
was 28 and 17 days of hospitalization on 100 patient-days 
(OR = 1.92; 95% CI 1.83–2.01; p < 0.001), respectively.
Table 1 Characteristics of patients to whom were prescribed antibiotics reserves (ARs) in pre- and intervention period
AR parenteral antibiotic reserves, ICD International Statistical Classification of Diseases and Related Health Problems
a All values are absolute frequencies with the percentage in parenthesis if not stated otherwise in a row
Variable Preintervention  perioda Intervention  perioda p
N on AR/overall N 249/3038 (8%) 96/3156 (3%) < 0.001
Bed-days on AR/overall bed-days 3701/20,902 (18%) 1683/20,722 (8%) < 0.001
Age, median (min–max) 69 (19–93) 70 (20–89) 0.240
Male sex 146 (59%) 49 (51%) 0.851
Admitted ward
 Internal 190 (76%) 68 (71%) 0.530
 Intensive care unit (ICU) 32 (13%) 13 (14%) 0.106
 Surgery 18 (7%) 13 (14%) 0.013
 Neurology 7 (3%) 2 (2%) 1.000
 Psychiatry 2 (1%) 0 (0%) 1.000
Fever 173 (72%) 70 (73%) 0.350
Comorbidities 226 (91%) 87 (94%) 0.931
Main ICD at hospital admission
 Diseases of the respiratory system (J00-J99) 61 (24%) 18 (19%) 0.332
 Certain infectious and parasitic diseases (A00–B99) 38 (15%) 15 (16%) 1.000
 Diseases of the digestive system (K00–K93) 34 (14%) 12 (12%) 0.863
 Malignant neoplasms (C00–C97) 25 (10%) 13 (14%) 0.459
 Diseases of the genitourinary system (N00–N99) 21 (8%) 12 (12%) 0.316
 Diseases of the circulatory system (I00–I99) 27 (11%) 6 (6%) 0.306
 Injuries (S00–T14) 14 (6%) 9 (9%) 0.242
 Other 29 (12%) 11 (11%) 0.143
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Secondary outcomes
Duration of treatment with AR prescribed in preinter-
vention and intervention periods were 11 and 4 days per 
100 patient days (OR = 2.7; 95% CI 2.5–2.9; p < 0.001), 
respectively. There was no statistical difference in both 
periods for risk factors for starting AR which were: male 
patients, median age of 70  years, internal ward admis-
sion, fever, existing comorbidities, disease of the respira-
tory system or certain infectious and parasitic diseases.
Discussion
Despite limited human resources of A-team and a short 
period, this study showed a significant impact on clini-
cal outcomes, focusing on parenteral ARs. Restrictive 
interventions helped to save last line antibiotics for their 
future use when they are really needed. The first A-team 
in Croatia, which consisted of ID specialist, clinical 
microbiologist and clinical pharmacist, demonstrated 
an immediate impact of their interventions. Example 
is reduction of duration of hospitalization of patients in 
intervention period by nearly 40% (from 28 to 17  days 
of hospitalization on 100 patient-days) with unaffected 
rehospitalizations. This brought highly needed evidence 
of positive effects of interventions on patient-centred 
outcomes [10, 22]. There was no statistical significance 
in rehospitalisation of patients on AR due to infection in 
first 2 months after discharge. However, in the 3rd month 
after discharge rehospitalisation was raised from 3 to 7% 
in intervention group which was statistically significant 
(p = 0.033). One of the reasons could be high risk of mor-
tality due to comorbidity that made patients more vulner-
able to influenza in influenza period that had the highest 
peak during January and February 2018 [23]. Winter was 
monitoring period for intervention group while preinter-
vention group was followed in autumn period, there-
fore patients had better chance to stay out of hospital. 
Second argument could be piperacillin 4  g/tazobactam 
0.5 g shortage due to production reasons in intervention 
period, but that needs further investigation [24].
Complete acceptance rate reflected agreement between 
A-team, treating physicians and their teams. In addition, 
this was also in accordance with final step of A-team 
intervention, which consisted of dispensing AR from 
hospital pharmacy only after validation from clinical 
pharmacist with access to medical record. Improving 
antimicrobial prescribing by clinical pharmacist is in 
correlation with previous studies and guidelines [25-27]. 
Multidisciplinary approach has proved to be beneficial 
in this study for understanding the A-team interventions 
and therefore accomplishing primary outcomes. Other 
studies have also proven importance of multidisciplinary 
approach but in other areas such as preoperative prophy-
laxis, broad-spectrum antibiotic consumption in various 
settings or timeliness of antimicrobial therapy in patients 
with positive blood cultures [28-31].
Risk factors for starting AR can be used in hospitals 
with resource limitation as a measure of estimation of 
patients that need special attention.
Furthermore, our aim correlates with WHO Global 
Action Plan on Antimicrobial Resistance to contain anti-
biotic resistance, optimize antibiotic treatment and to 
preserve ’last-resort’ antibiotics [32].
This study suggests that A-team restrictive interven-
tions focused on parenteral ARs are useful strategy in 
improving antimicrobial prescribing without compromis-
ing clinical outcomes. Moreover, we proved possibility of 
achieving our goals despite limited human resources and 
short period. In addition, results could serve as evidence 
for including clinical pharmacists in clinical medicine in 
Croatia. Our research demonstrated the best practice 
that could be transferred to other national and transna-
tional institutions.
Limitations
Study was a single centre non-randomized study, which 
was the first limitation. However, it was difficult to 
blind investigators or participants in trial of antimicro-
bial stewardship. Second limitation was two periods of 
Table 2 Primary outcomes
AR parenteral antibiotic reserves, ICD International Statistical Classification of Diseases and Related Health Problems
a All values are absolute frequencies with the percentage in parenthesis if not stated otherwise in a row
Variable Preintervention  perioda Intervention  perioda p
N on AR/overall N 249/3038 (8%) 96/3156 (3%)  < 0.001
Duration of hospitalisation of patients on AR on 
100 patient days
28 17  < 0.001
Rehospitalization in
 1st month 13/207 (6) 6/75 (8) 0.597
 2nd month 10/203 (5) 7/68 (10) 0.146
 3rd month 6/200 (3) 5/67 (7) 0.033
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3 months which were short to prove sustainability, but 
we demonstrated A-team programme’s value by focus-
ing on outcome measures. Third, A-team just focused 
on AR and not on other antibiotics, which should be 
investigated in future studies. Nonetheless, we wanted 
to investigate the effectiveness of A-team on a small but 
very important group of antibiotics that are costly and 
under restricted use. In addition, the aim was to show 
our positive results to managers who could give us 
more resources to broaden our interventions to other 
classes of antimicrobials. Finally, we did not investigate 
AMR due to too short period of follow up, but this is 
our plan for future.
The future research is needed with a larger multi-
centred study, more extended period of intervention, 
follow up and feedback of A-team with particular 
emphasis on effectiveness of clinical pharmacy services.
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